Heron Therapeutics, Inc. (HRTX) reports Q1 2026 earnings of $34.7M, with Zinrelef and Aponvi showing strong growth. Future outlook remains positive.

Key Takeaways

• Total net revenue for Q1 2026 reached $34.7 million, slightly below expectations due to weather-related impacts but showing recovery trends.
• Demand for Zinrelef grew 22% year-over-year, outpacing the broader local anesthetic market, with average daily units and ordering accounts continuing to trend upward.
• Aponvi reported a staggering 68% year-over-year growth in demand units, with an all-time high of 371 ordering accounts.
• Management maintains full-year guidance of $173 million to $183 million in net product sales and $10 million to $20 million in adjusted EBITDA.
• The company is expanding its sales force for both Zinrelef and Aponvi, targeting enhanced market penetration across key geographies.

Financial Performance

Heron Therapeutics, Inc. reported its Q1 2026 earnings, showcasing a resilient commercial performance despite external challenges. The total net revenue for the quarter was $34.7 million, which reflects a slight dip from expectations primarily attributed to adverse weather conditions that affected elective surgical procedures. The gross margin stood at 69%, lower than the typical low to mid-70s percentage range due to the utilization of a secondary supplier for Synvanti, which operates at a higher production cost. Management expects margins to normalize once this transition is complete.

Adjusted EBITDA for the quarter was reported at negative $727,000, but leadership emphasized that this was a temporary setback. As weather-related surgeries are rescheduled, revenue is expected to rebound, with March revenue alone exceeding $15 million, setting a positive tone for the upcoming quarters.

Strategic Initiatives

The company has been proactive in enhancing its product offerings and market strategies. Key highlights from the recent earnings call include:

• Zinrelef: The demand unit growth of 22% year-over-year showcases the product's strong market position. The implementation of a permanent J-code for reimbursement and the introduction of Ignite 2.0, which expands targeted accounts by 38%, are pivotal strategies aimed at solidifying Zinrelef's market share.
• Aponvi: The product experienced significant growth, with demand units increasing by 68% year-over-year. Aponvi's approval in 1,903 accounts opens doors to a substantial addressable market, with management highlighting the importance of its inclusion in the fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV).
• Synvanti: Despite being in a competitive landscape, Synvanti has maintained a stable market share of 25%. The company's dedication to disciplined pricing strategies ensures long-term sustainability while enhancing demand across existing accounts.

The expansion of Heron's sales force is a critical component of its strategic initiatives, targeting key geographies and bolstering its product adoption rates. This dual sales force expansion is expected to enhance the company's share of voice in the market, positioning it favorably against competitors.

Future Outlook

Heron Therapeutics is optimistic about its future growth trajectory, reaffirming its full-year guidance for net product sales between $173 million and $183 million and adjusted EBITDA between $10 million and $20 million. Management is focused on driving sales through:

• Increased sales force: The expansion of dedicated teams for both Zinrelef and Aponvi is set for Q3 2026, aiming to penetrate additional markets effectively.
• Enhanced reimbursement landscape: The introduction of new reimbursement codes and the favorable positioning within clinical guidelines are expected to simplify access and increase adoption rates.
• Market recovery: The anticipated recovery from weather-related disruptions is expected to contribute positively to revenue in subsequent quarters, reinforcing the company's confidence in achieving its financial targets.

The management team's commitment to disciplined cost management and market adaptability continues to inspire confidence among investors, as they navigate through external challenges while strategically positioning the company for long-term growth.

In conclusion, Heron Therapeutics, Inc. demonstrated resilience in Q1 2026, with promising growth in product demand and a strategic focus on expanding market share. The company is well-positioned to capitalize on recovery trends and maintain its growth trajectory moving forward, making it an intriguing prospect for investors.

This analysis is based on public earnings call materials and is not investment advice.